G1 Therapeutics

G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Thursday, April 4, 2024
G1 Therapeutics, Conference, Therapy

RESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 8:45 AM ET.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 8:45 AM ET.

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, April 1, 2024
Employment, G1 Therapeutics, RSU, Therapy

RESEARCH TRIANGLE PARK, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 3,000 shares of G1’s common stock and 1,500 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 3,000 shares of G1’s common stock and 1,500 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).
  • These equity awards were granted as an inducement material to the new employee becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Amended and Restated 2021 Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of G1 (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with G1, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The stock options and RSUs are subject to the terms and conditions of the Amended and Restated 2021 Plan.

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 1, 2024
G1 Therapeutics, Therapy, Employment, RSU

RESEARCH TRIANGLE PARK, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,100 shares of G1’s common stock and 1,050 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,100 shares of G1’s common stock and 1,050 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).
  • These equity awards were granted as an inducement material to the new employee becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Amended and Restated 2021 Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of G1 (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with G1, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The stock options and RSUs are subject to the terms and conditions of the Amended and Restated 2021 Plan.

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, February 28, 2024
G1 Therapeutics, Breast cancer, Carboplatin, Research, PIN, SCLC, Telephone, Update, J. P. Morgan, DMC, Food, Growth, SACT, G1, Trilaciclib, Hospital, ADC, OS, Conjugation, GAAP, Event, Therapy, Webcast, Patent, Patient, Acceleration, Clinical trial, Survival, Oncology, ITT, Pharmaceutical industry

G1 recognized total revenues of $14.9 million and $82.5 million for the fourth quarter and full year of 2023, respectively.

Key Points: 
  • G1 recognized total revenues of $14.9 million and $82.5 million for the fourth quarter and full year of 2023, respectively.
  • Operating expenses for the fourth quarter of 2023 were $23.8 million, compared to $41.1 million for the fourth quarter of 2022.
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $7.4 million, compared to $16.6 million for the fourth quarter of 2022.
  • The net loss for the fourth quarter of 2023 was $10.9 million, compared to $33.6 million for the fourth quarter of 2022.

G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Retrieved on: 
Tuesday, February 27, 2024
G1 Therapeutics, Therapy, Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in a Breast & Lung Cancer Corporate Panel Discussion during the TD Cowen 44th Annual Health Care Conference on Wednesday March 6, 2024 at 9:10 AM EST.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in a Breast & Lung Cancer Corporate Panel Discussion during the TD Cowen 44th Annual Health Care Conference on Wednesday March 6, 2024 at 9:10 AM EST.

G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024

Retrieved on: 
Thursday, February 15, 2024
G1 Therapeutics, Event, Therapy, PIN, Webcast

RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the fourth quarter and full year 2023 on Wednesday February 28, 2024, at 8:30 a.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the fourth quarter and full year 2023 on Wednesday February 28, 2024, at 8:30 a.m.
  • While not required, it is recommended that you join 10 minutes prior to the start of the event.
  • A live and archived webcast will be available on the Events & Presentations page of the company’s website: www.g1therapeutics.com .
  • The webcast will be archived on the same page for 90 days following the event.

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee

Retrieved on: 
Monday, February 12, 2024
G1 Therapeutics, Carboplatin, Breast cancer, Bone marrow, Data monitoring committee, DMC, OS, Safety, Therapy, TNBC, Patient, Survival, ITT, Rated R, Pharmaceutical industry

The DMC did not express any concerns regarding safety or recommend any other changes to the study.

Key Points: 
  • The DMC did not express any concerns regarding safety or recommend any other changes to the study.
  • G1 remains blinded to all data as the early stopping criteria were not met during the interim analysis.
  • PRESERVE 2 is a global, multi-center, randomized placebo-controlled, line extension pivotal Phase 3 trial of trilaciclib in patients with locally advanced unresectable or metastatic TNBC.
  • Patients meeting eligibility requirements were randomized 1:1 to receive either trilaciclib or placebo administered prior to first-line gemcitabine and carboplatin (GCb).

G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Patient, Conference, TNBC, Survival, Woman, G1 Therapeutics, Trilaciclib, Therapy, Hospital, Practitioner, Interim, SACT, OS, ADC, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced new clinical, commercial and corporate updates, including encouraging preliminary overall survival (OS) data from the Company’s ongoing Phase 2 trial of trilaciclib in combination with the ADC sacituzumab govitecan (SG) in patients with TNBC. This update is now available in a new corporate presentation which will be used during the 42nd Annual J.P. Morgan Healthcare Conference and can be accessed here.

Key Points: 
  • This update is now available in a new corporate presentation which will be used during the 42nd Annual J.P. Morgan Healthcare Conference and can be accessed here .
  • The Company expects to provide updated OS data from this study mid-2024.
  • Strong COSELA® (trilaciclib) volume growth in 4Q23: COSELA vial volume grew 19% in 4Q23 over the prior quarter as platinum-based chemotherapy shortages began to abate.
  • COSELA vial volume in October, November, and December 2023 represented the highest volume months since launch.

G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024
Conference, G1 Therapeutics, Therapy

RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024, at 1:30 PM PST.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024, at 1:30 PM PST.

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, January 2, 2024
Therapy, G1 Therapeutics, Employment, RSU

RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,300 shares of G1’s common stock and 3,000 restricted stock units (RSUs) to three hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,300 shares of G1’s common stock and 3,000 restricted stock units (RSUs) to three hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).
  • These equity awards were granted as an inducement material to the new employee becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Amended and Restated 2021 Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of G1 (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with G1, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The stock options and RSUs are subject to the terms and conditions of the Amended and Restated 2021 Plan.